GLP-1 agonists for metabolic disorders in schizophrenia
Patients with schizophrenia have a 2- to 3-fold higher mortality rate compared with the general population. A high prevalence of obesity, cardiometabolic disorders, and type 2 diabetes among these patients largely explains the increased cardiovascular risk (Correll et al., 2017).
Source: Schizophrenia Research - Category: Psychiatry Authors: Youssef Kouidrat, Ali Amad Tags: Letter to the Editor Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Obesity | Schizophrenia